CS Medica 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Lone Henriksen

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	29.4%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Jun 04

CEO 보상 분석

Lone Henriksen 의 보수는 CS Medica 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-DKK 12m
Mar 31 2024	n/a	n/a	-DKK 13m
Dec 31 2023	n/a	n/a	-DKK 14m
Sep 30 2023	n/a	n/a	-DKK 15m
Jun 30 2023	n/a	n/a	-DKK 11m
Mar 31 2023	n/a	n/a	-DKK 11m
Dec 31 2022	n/a	n/a	-DKK 12m
Sep 30 2022	n/a	n/a	-DKK 11m
Jun 30 2022	n/a	n/a	-DKK 10m
Mar 31 2022	n/a	n/a	-DKK 5m
Dec 31 2021	n/a	n/a	-DKK 2m
Sep 30 2021	n/a	n/a	DKK 648k
Jun 30 2021	n/a	n/a	DKK 29k
Sep 30 2020	DKK 960k	DKK 960k	-DKK 55k

보상 대 시장: Swedish 시장에서 비슷한 규모의 회사에 비해 Lone 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Lone 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Lone Henriksen (54 yo)

no data

테뉴어

DKK 960,000

보상

Ms. Lone Henriksen serves as Chief Executive Officer and Chief Scientific Officer of CS Medica A/S and was its Partner. She is a founder of CS Medica A/S. Ms. Henriksen holds a B.Sc. in Biochemistry and a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Lone Henriksen	CEO, Chief Scientific Officer & Founder	no data	DKK 960.00k	29.45% DKK 15.5m
Gitte Henriksen	Founder	1.8yrs	DKK 961.00k	29.24% DKK 15.4m
Heidi Ahlefeldt-Laurvig	COO & Chief Marketing Officer	2.5yrs	데이터 없음	데이터 없음
Cathy Jolibois	Chief Sales Manager	no data	데이터 없음	데이터 없음
Mikkel Nielsen	C C O	1.8yrs	데이터 없음	데이터 없음
Suzan Al-shuweli	CQO & PRRC	1.2yrs	데이터 없음	데이터 없음
Kamlesh Vora	Managing Director of Cannordic India	1.3yrs	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: CSMED 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gitte Henriksen	Founder	no data	DKK 961.00k	29.24% DKK 15.4m
Karsten Adelmark	Director	1.8yrs	데이터 없음	데이터 없음
Eske Dyva	Member of Advisory Board	no data	데이터 없음	데이터 없음
Anders Permin	Director	no data	DKK 25.00k	데이터 없음
Steen Søndergaard	Member of Advisory Board	no data	데이터 없음	데이터 없음
Jesper Halle	Director	less than a year	데이터 없음	데이터 없음
Flemming Heegaard	Chairman of the Board	less than a year	데이터 없음	데이터 없음
Ib Madsen	Director	less than a year	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: CSMED 의 이사회는 경험(평균 재직 기간 0.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

CS Medica 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

CS Medica A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body

CS Medica A/S, Annual General Meeting, Feb 09, 2023

No independent directors

CS Medica A/S and CanNordic A/S Announce the Resignation of Bo Unéus as Board Member

No independent directors

CS MEDICA A/S Appoints Heidi Ahlefeldt-Laurvig as Chief Growth Officer and Chief Marketing Officer, Effective May 1, 2022

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

New major risk - Market cap size

CS Medica A/S Announces Approval of CANNASEN Pain Patch in Malaysia and Trademark Registration in Thailand

Third quarter 2024 earnings released

CS MEDIC Receives "Intention to Grant" for European Patent Application Concerning Cannasen® Psoriasis Gel, Reinforcing Leadership in Cbd-Infused Dermatological Innovations

CS Medica A/S to Report Q3, 2024 Results on Jul 31, 2024

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Second quarter 2024 earnings released

CS Medica A/S to Report Fiscal Year 2024 Results on Nov 28, 2024

CS Medica A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia

CS Medica A/S to Report 3 Months Period Ending Dec 31, 2023 Results on Mar 29, 2024

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report 3 Months 2023 Final Results on Apr 24, 2024

CS Medica A/S Announces FDA Authorization for Commercialization for Eight Products in the U.S. Market

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report Q4, 2024 Results on Nov 14, 2024

Cs Medica A/S Announces Indian State's Fda Approval for Two Cosmetic Products

New major risk - Share price stability

New major risk - Market cap size

CS Medica A/S to Report Q3, 2023 Results on Aug 08, 2023

CS Medica A/S to Report Q3, 2023 Results on Jul 18, 2023

CS Medica A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body

New major risk - Market cap size

CS Medica A/S Announces Positive Results from Clinical Trial of Nasal Protect Gel for Hay Fever/Allergic Rhinitis

CS Medica A/S to Report Fiscal Year 2022 Final Results on Jan 27, 2023

CS Medica A/S to Report Q1, 2023 Results on Feb 17, 2023

CS Medica A/S, Annual General Meeting, Feb 09, 2023

CS Medica A/S Provides Update on Clinical Trials

Full year 2022 earnings released: kr.0.90 loss per share (vs kr.0.059 profit in FY 2021)

No independent directors

CS Medica A/S and CanNordic A/S Announce the Resignation of Bo Unéus as Board Member

CS Medica A/S Provides Revenue Guidance for the Year 2022

CS MEDICA Provides Patent Update

CS Medica A/S to Report Fiscal Year 2022 Results on Nov 18, 2022

CS MEDICA A/S Reports Proof of Concept in the Results from the Clinical Trial on NGP-01 (Cannasen®Cbd Psoriasis Gel) Against Placebo

CS MEDICA A/S Announces Groundbreaking Discovery in the Natural Cannabinoid CBD's Activity in the Body

Cs Medica Announces Positive Clinical Trial Results from the Final Report on Nga-01 Gel & Nsa-01 Capsule in Combination Against Placebo

CS Medica A/S Reports the Results from the Clinical Trial on NGA-01(CANNASEN®CBD Arthritis Gel) Against Placebo

CS MEDICA A/S Provides Revenue Guidance for 2023/2024

No independent directors

CS Medica Receives the Final Approval from Hong Kong Customs, the Drug Registration Office

CS MEDICA A/S Provides Patent Update

CS MEDICA A/S Finalizes THC Test At PPB Level on Their Cannasen®Cbd Products to Comply with the Strict Regulations on the Asian Market

CS MEDICA A/S Appoints Heidi Ahlefeldt-Laurvig as Chief Growth Officer and Chief Marketing Officer, Effective May 1, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

CS MEDICA A/S Reaffirms Revenue Guidance for the Fiscal Year 2022

CS MEDICA A/S Announces Their CANNANSEN®CBD Anti-Hair Loss Serum Approves in the United Arab Emirates

CS MEDICA A/S Announces an Additional Five Intellectual Property Rights Registrations

No independent directors

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령